Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Glycoconjugates and their use as potential vaccines against infection by Shigella flexneri

a technology of shigella flexneri and glycoconjugate, which is applied in the field of eliciting an immunogenic response in mammals, can solve the problems of not being able to improve rapidly and the control of these parameters is somewhat difficult, so as to prevent, treat, or ameliorate infection and disease

Active Publication Date: 2012-02-28
INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2
View PDF7 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The proposed solution induces immunogenic responses that generate protective antibodies against S. flexneri 2a, offering potential prevention and treatment options for shigellosis, while also enabling diagnostic applications.

Problems solved by technology

Occurrence of the disease is seen as a correlate of sanitary conditions, and those are not likely to improve rapidly in areas at risk.
It is reasonably admitted that control of these parameters is somewhat difficult when dealing with polysaccharides purified from bacterial cell cultures.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Glycoconjugates and their use as potential vaccines against infection by <i>Shigella flexneri</i>
  • Glycoconjugates and their use as potential vaccines against infection by <i>Shigella flexneri</i>
  • Glycoconjugates and their use as potential vaccines against infection by <i>Shigella flexneri</i>

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0043]Oligo- and Polysaccharides:

[0044]This invention provides a synthetic, semi-synthetic, natural, modified-natural or recombinant oligo- or polysaccharide containing subunits from the list L1.

[0045]Methods for synthesizing S. flexneri 2a di- tri-, tetra, penta and octasaccharides are know from the prior art (F. Segat Dioury et al., Tetrahedron Asymmetry, 13, 2002, 2211-2222; C. Costachel et al., J. Carbohydrate Chemistry, 19(9) 2000, 1131-1150; L. Mulard et al., J. Carbohydrate Chemistry, 19(7), 2000, 849-877 F. Belot et al., Tetrahedron Letters, 43, 2002, 8215-8218; L. Mulard et al., Tetrahedron 58, 2002, 2593-2604; L. Mulard et al., J. Carbohydrate Chemistry, 19(2), 2000, 193-200).

[0046]An improved method to synthesize oligo- or polysaccharides is set forth in the examples below. Notably the synthesis of a decasaccharide was performed by condensation of two pentasaccharide intermediates.

DEFINITIONS

[0047]“oligosaccharide” as defined herein, is a carbohydrate containing from two ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by S. Flexneri.

Description

FIELD OF THE INVENTION[0001]This invention relates to compositions and methods for eliciting an immunogenic response in mammals, including responses that provide protection against, or reduce the severity of bacterial infections. More particularly it relates to the use of oligo- or polysaccharides obtained from natural sources and / or through synthesis or recombinant technology, and conjugates thereof to induce serum antibodies having protective activity against Shigella flexneri, in particular S. flexneri serotype 2a. These saccharides and / or conjugates thereof are useful as vaccines to induce serum antibodies which have protective activity against S. flexneri, in particular S. flexneri type 2a, and are useful to prevent and / or treat shigellosis caused by S. flexneri. [0002]The present invention also relates to diagnostic tests for shigellosis using one or more of the oligo- or polysaccharides, conjugates or antibodies described above.BACKGROUND OF THE INVENTION[0003]Since the disco...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): C12P19/00C12P19/12C07K1/00A61K39/02A61K39/112A61K47/48C07K16/12G01N33/563G01N33/569
CPCA61K39/0283A61K47/48146A61K47/4823A61K47/48261A61K47/4833C08B37/006C07K16/1228G01N33/563G01N33/56916C07H3/06A61K2039/6031A61K2039/625C07K2317/565A61K2039/6037A61K47/557A61K47/61A61K47/6415A61K47/646A61P31/04Y02A50/30
Inventor PHALIPON, ARMELLENATO, FARIDAMULARD, LAURENCESANSONETTI, PHILIPPEBALEUX, FRANCOISEBELOT, FREDERICGRANDJEAN, CYRILLE
Owner INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com